Hemogenyx Pharmaceuticals PLC Announces Update on CDX Antibody Development

Hemogenyx制药公司宣布CDX抗体开发的最新进展

2021-01-13 23:20:50 BioSpace

本文共2072个字,阅读需6分钟

LONDON, UK / ACCESSWIRE / January 13, 2021 / Hemogenyx Pharmaceuticals plc , the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully completed the development of its CDX antibody with a leading global pharmaceutical company . As a result of the Company's successful collaboration with GlobalCo, the Company has chosen a clone of its CDX antibody that is ready for investigational new drug application-enabling studies, a significant step toward clinical trials. On 14 May 2018, the Company announced a collaboration with GlobalCo to work on its CDX antibody. Under the Agreement, which stipulated that GlobalCo's identity remain anonymous for the time being, Hemogenyx Pharmaceuticals received, free of charge, technical support, access to advanced methods of discovering, developing and engineering antibodies, and certain intellectual property necessary for the successful preclinical development of the Company's lead candidate bi-specific CDX antibody for the treatment of acute myeloid leukemia ("AML"). This work complemented the Company's own development work that was being undertaken. With the phase of the Agreement relating to the development of the antibody completed, under the Agreement, as of 11 January 2021, GlobalCo has three months to exercise an option to license the Company's intellectual property necessary to exploit the CDX antibody on an exclusive worldwide basis ("Option"). In the event GlobalCo and Company are unable to reach an exclusive licensing agreement within six months of GlobalCo's exercise of the Option, if any, or if GlobalCo does not exercise the Option, Hemogenyx Pharmaceuticals will have three months to exercise an option to license the GlobalCo's intellectual property necessary to exploit the CDX antibody on an exclusive worldwide basis, followed by six months to reach an exclusive licensing agreement. In either scenario, the Directors are confident that a successful outcome will be achieved to take the development of the CDX antibody forward toward clinical trials. In the meantime, the Company and GlobalCo will continue developing the CDX antibody asset. Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "We are extremely pleased with the outcome of our collaboration with GlobalCo, which has resulted in a CDX antibody that is ready to be developed for clinical trials. I am very proud of the Company's team of scientists who, without a doubt, have proven that Hemogenyx Pharmaceuticals is capable of performing cutting edge research and development of the highest calibre. The completion of the development of the CDX antibody with GlobalCo is a key milestone on our path to creating an effective treatment for patients suffering from AML, and we look forward to entering into the next phase of negotiations with GlobalCo." About AML AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than 30% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective form of therapy being developed by Hemogenyx Pharmaceuticals. The successful development of the new therapy for AML would have a major impact on treatment and survival rates for the disease. Market Abuse Regulation (MAR) Disclosure Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation No 596/2014 until the release of this announcement. Enquiries: Hemogenyx Pharmaceuticals plc https://hemogenyx.com Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@hemogenyx.com Peter Redmond, Director peter.redmond@hemogenyx.com SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470 Matthew Johnson, Vadim Alexandre, Adam Cowl Peterhouse Capital Limited Tel: +44 (0)20 7469 0930 Lucy Williams, Duncan Vasey, Charles Goodfellow About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development. For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. SOURCE: Hemogenyx Pharmaceuticals PLC View source version on accesswire.com: https://www.accesswire.com/624100/Hemogenyx-Pharmaceuticals-PLC-Announces-Update-on-CDX-Antibody-Development
英国伦敦/ACCESSWIRE/2021年1月13日/开发血液疾病新疗法和治疗的生物制药集团Hemogenyx Pharmaceuticals plc高兴地宣布,与一家领先的全球制药公司成功完成了其CDX抗体的开发。由于该公司与GlobalCo公司的成功合作,该公司选择了一种CDX抗体的克隆,该克隆已准备好进行新药应用研究,这是向临床试验迈出的重要一步。 于二零一八年五月十四日,本公司宣布与GlobalCo合作研发其CDX抗体。该协议规定Globalcol的身份暂时不具名,根据该协议,Hemogenyx制药公司免费获得技术支持,获得发现,开发和设计抗体的先进方法,以及成功开发该公司用于治疗急性髓细胞白血病(AML)的主要候选双特异性CDX抗体所必需的某些知识产权。这项工作补充了公司本身正在进行的发展工作。 随着与抗体开发有关的协议阶段的完成,根据协议,截至2021年1月11日,GlobalCo有三个月的时间行使选择权,许可公司在全球范围内独家开发CDX抗体所需的知识产权(选择权)。如果GlobalCo和公司无法在GlobalCo行使选择权后的六个月内达成排他性许可协议,或者GlobalCo不行使选择权,Hemogenyx制药公司将有三个月的时间行使选择权,许可GlobalCo在全球范围内排他性利用CDX抗体所必需的知识产权,然后在六个月内达成排他性许可协议。 无论在哪种情况下,董事们都有信心取得成功的结果,从而将CDX抗体的开发推向临床试验。同时,公司和GlobalCo将继续开发CDX抗体资产。 Hemogenyx制药公司首席执行官兼联合创始人Vladislav Sandler博士评论说: “我们对我们与GlobalCo公司的合作成果感到非常高兴,该合作成果产生了一种CDX抗体,该抗体已准备好用于临床试验。我为公司的科学家团队感到非常自豪,毫无疑问,他们已经证明Hemogenyx制药公司有能力进行最高水平的尖端研究和开发。与GlobalCo公司完成CDX抗体的开发是我们为AML患者创造有效治疗方法道路上的一个关键里程碑,我们期待着与GlobalCo公司进入下一阶段的谈判。“ 关于AML AML是成人最常见的急性白血病类型,生存率较低(成人5年生存率低于30%),目前采用化疗治疗,而不是Hemogenyx制药公司正在开发的潜在的更良性和有效的治疗形式。AML新疗法的成功开发将对该病的治疗和生存率产生重大影响。 市场滥用管制披露 就第596/2014号规例第7条而言,本公告所载若干资料在本公告发布前应视为内幕消息。 查询: Hemogenyx制药公司 https://hemogenyx.com Vladislav Sandler博士,首席执行官兼联合创始人 headquarters@hemogenyx.com Peter Redmond,主任 电子邮件:peter.redmond@hemogenyx.com SP Angel企业融资有限责任公司 电话:+44(0)20 3470 0470 Matthew Johnson,Vadim Alexandre,Adam Cowl 彼得豪斯资本有限公司 电话:+44(0)20 7469 0930 露西·威廉姆斯,邓肯·维西,查尔斯·古德费罗 关于Hemogenyx制药公司 Hemogenyx Pharmaceuticals plc是一家上市公司(LSE:HEMO),总部设在伦敦,其在美国的运营子公司Hemogenyx Pharmaceuticals LLC和Immugenyx LLC位于纽约市,拥有最先进的研究设施。 该公司是一个临床前阶段的生物制药集团,开发新的药物和治疗方法,以治疗血液和自身免疫疾病,并将骨髓移植的治疗能力带给更多患有否则无法治愈的威胁生命的疾病的患者。Hemogenyx制药公司正在开发几种不同的,互补的候选产品,以及作为新产品开发引擎的平台技术。 50多年来,骨髓移植一直被用于挽救患有血液病患者的生命。然而,与骨髓移植相关的毒性和死亡风险意味着该程序只能作为最后手段使用。该公司的技术有潜力使更多患有白血病和淋巴瘤等毁灭性血液疾病,以及多发性硬化症,再生障碍性贫血和系统性红斑狼疮(lupus)等严重自身免疫性疾病的患者从骨髓移植中获益。 本信息由伦敦证券交易所新闻服务机构RNS提供。RNS经金融行为监管局批准作为联合王国的主要信息提供者。与使用和分发本信息有关的条款和条件可能适用。欲了解更多信息,请联系rns@lseg.com或访问www.rns.com。 资料来源:Hemogenyx Pharmaceuticals PLC 在accesswire.com上查看源版本: https://www.accesswire.com/624100/hemogenyx-pharmaceuticals-plc-announces-update-on-cdx-antibody-development

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文